| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Pharmacology, Baylor College of Medicine, Houston, Texas 77030
Tumor nucleoli were treated with polyclonal antisera to normal human tissue nucleoli to block some determinants common to tumor and normal tissue nculeoli. Immunization of mice with these immune complexes resulted in the development of a monoclonal antibody (FB2) to a novel Mr 120,000 nucleolar proliferation-associated antigen. By indirect immunofluorescence, antibody FB2 produced bright nucleolar staining in a variety of malignant tumors, including cancers of the breast, liver, gastrointestinal tract, genitourinary tract, blood, lymph system, lung, and brain. Although specific nucleolar immunofluorescence was not detectable in most normal tissues, it was detectable in some proliferating nonmalignant tissues including spermatogonia of the testes, ductal regions of hypertrophied prostates, and phytohemagglutinin-stimulated lymphocytes. The Mr 120,000 antigen was not detectable in 48-h serum-deprived HeLa cells but was readily detectable (within 30 min) following serum refeeding. The Mr 120,000 antigen was not detected in retinoic acid-treated HL-60 cells following morphological differentiation but was detectable in 48-h phytohemagglutinin-treated lymphocytes. These studies suggest that the Mr 120,000 antigen is a proliferation-associated antigen which plays a role in the early G1 phase of the cell cycle.
1 Supported by Cancer Research Center Grant CA-10893, P1, awarded by the National Cancer Institute, Department of Health and Human Services, Public Health Service; The DeBakey Medical Foundation; the Davidson Fund; the Pauline Sterne Wolff Memorial Foundation; the H. Leland Kaplan Cancer Research Endowment; the Linda and Ronnie Finger Cancer Research Endowment Fund; the William S. Farish Fund; and the Sally Laird Hitchcock Fund.
2 To whom requests for reprints should be addressed.
Received 4/13/87. Revised 8/10/87. Revised 11/ 2/87. Accepted 11/11/87.
This article has been cited by other articles:
![]() |
G. Sato, Y. Saijo, B. Uchiyama, N. Kumano, S.-i. Sugawara, S. Fujimura, M. Sato, M. Sagawa, K. Ohkuda, K. Koike, et al. Prognostic Value of Nucleolar Protein p120 in Patients With Resected Lung Adenocarcinoma J. Clin. Oncol., September 1, 1999; 17(9): 2721 - 2721. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Marciniak, D. B. Lombard, F. B. Johnson, and L. Guarente Nucleolar localization of the Werner syndrome protein in human cells PNAS, June 9, 1998; 95(12): 6887 - 6892. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Amann, V. J. Kidd, and J. M. Lahti Characterization of Putative Human Homologues of the Yeast Chromosome Transmission Fidelity Gene, CHL1 J. Biol. Chem., February 7, 1997; 272(6): 3823 - 3832. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. T. Meier and U. T. Meier Comparison of the Rat Nucleolar Protein Nopp140 with Its Yeast Homolog SRP40. DIFFERENTIAL PHOSPHORYLATION IN VERTEBRATES AND YEAST J. Biol. Chem., August 9, 1996; 271(32): 19376 - 19384. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Kill Localisation of the Ki-67 antigen within the nucleolus. Evidence for a fibrillarin-deficient region of the dense fibrillar component J. Cell Sci., January 6, 1996; 109(6): 1253 - 1263. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |